A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy

Biomed Res Int. 2014:2014:213239. doi: 10.1155/2014/213239. Epub 2014 Sep 7.

Abstract

Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Confidence Intervals
  • Contrast Media / adverse effects*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / prevention & control*
  • Odds Ratio
  • Randomized Controlled Trials as Topic*
  • Reproducibility of Results
  • Risk Factors

Substances

  • Contrast Media
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors